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Abstract
Aims/hypothesis The aim of this study was to determine
whether random non-fasting C-peptide (rCP) measurement
can be used to assess hypoglycaemia risk in insulin-treated
type 2 diabetes.
Methods We compared continuous glucose monitoring-
assessed SD of blood glucose and hypoglycaemia duration
in 17 patients with insulin-treated type 2 diabetes and severe
insulin deficiency (rCP< 200 pmol/l) and 17matched insulin-
treated control patients with type 2 diabetes but who had
preserved endogenous insulin (rCP > 600 pmol/l). We then
assessed the relationship between rCP and questionnaire-
based measures of hypoglycaemia in 256 patients with
insulin-treated type 2 diabetes and a comparison group of
209 individuals with type 1 diabetes.
Results Continuous glucose monitoring (CGM)-assessed glu-
cose variability and hypoglycaemia was greater in individuals
with rCP < 200 pmol/l despite similar mean glucose. In those
with low vs high C-peptide, SD of glucose was 4.2 (95% CI
3.7, 4.6) vs 3.0 (2.6, 3.4) mmol/l (p < 0.001). In the low-C-
peptide vs high-C-peptide group, the proportion of individuals
experiencing sustained hypoglycaemia ≤ 4 mmol/l was 94%
vs 41% (p < 0.001), the mean rate of hypoglycaemia was 5.5
(4.4, 6.7) vs 2.1 (1.4, 2.9) episodes per person per week
(p = 0.004) and the mean duration was 630 (619, 643) vs
223 (216, 230) min per person per week (p = 0.01).
Hypoglycaemia ≤ 3 mmol/l was infrequent in individuals with
preserved C-peptide (1.8 [1.2, 2.6] episodes per person per
week vs 0.4 [0.1, 0.8] episodes per person per week for low
vs high C-peptide, p = 0.04) and only occurred at night. In a
population-based cohort with insulin-treated type 2 diabetes,
self-reported hypoglycaemia was twice as frequent in those
with rCP < 200 pmol/l (OR 2.0, p < 0.001) and the rate of
episodes resulting in loss of consciousness or seizure was five
times higher (OR 5.0, p = 0.001). The relationship between
self-reported hypoglycaemia and C-peptide was similar in
individuals with type 1 and type 2 diabetes.
Conclusions/interpretation Low rCP is associated with
increased glucose variability and hypoglycaemia in patients
with insulin-treated type 2 diabetes and represents a practical,
stable and inexpensive biomarker for assessment of
hypoglycaemia risk.
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Diabetes . Hypoglycaemia . Insulin . Type 2 diabetes
Abbreviations
CGM Continuous glucose monitoring
DARE Diabetes Alliance for Research in England
IA2 Islet antigen 2
LBGI Low blood glucose index
MAGE Mean amplitude of glycaemic excursions
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00125-017-4449-2) contains peer-reviewed but
unedited supplementary material, which is available to authorised users.
* Suzy V. Hope
S.V.Hope@exeter.ac.uk
* Angus G. Jones
angus.jones@exeter.ac.uk
1 NIHR Exeter Clinical Research Facility, University of Exeter
Medical School and Royal Devon and Exeter NHS Foundation Trust,
Barrack Road, Exeter EX2 5DW, UK
2 Diabetes and Vascular Medicine, University of Exeter Medical
School and Royal Devon and Exeter NHS Foundation Trust,
Exeter, UK
3 Department of Diabetes, King’s College London, London, UK
Diabetologia
DOI 10.1007/s00125-017-4449-2
rCP Random non-fasting C-peptide
SMBG Self-monitoring of blood glucose
Introduction
Individuals with type 1 diabetes usually develop severe
endogenous insulin deficiency, which results in high glucose
variability and hypoglycaemia risk [1–4]. Treatment guidelines
for type 1 diabetes, therefore, incorporate early intensive
strategies to minimise hypoglycaemia, including multiple daily
insulin injections, carbohydrate counting and insulin pumps [5].
Endogenous insulin deficiency is best assessed using C-
peptide [6]. In the DCCT study, intensively treated
participants with type 1 diabetes with mixed meal test-
stimulated C-peptide < 200 pmol/l had three times as many
episodes of severe hypoglycaemia than other participants,
despite having higher HbA1c [2, 3]. This threshold of
200 pmol/l is commonly described as identifying absolute
insulin deficiency, although modern assays can measure
below this range [7, 8] and a relationship between
hypoglycaemia and lower levels of C-peptide has been
described [9, 10].
We have recently demonstrated that a random non-fasting
plasma C-peptide (rCP) sample is a sensitive and specific
measure for mixed meal tolerance test-defined absolute
insulin deficiency (stimulated C-peptide < 200 pmol/l), with
the same C-peptide threshold having a sensitivity and
specificity of 100% and 93%, respectively [11]. As C-
peptide is stable in whole blood collected into EDTA for
> 24 h [12], this means severe insulin deficiency can be
identified from a routine non-fasting blood sample when a
patient is seen in the clinic.
Severe insulin deficiency can occur in insulin-treated
patients who have clinical features consistent with type 2
diabetes, but the deficiency is usually not recognised
[13–16]. This is likely to be an increasing problem as obesity
rates increase, making clinical classification more difficult.
We hypothesise that individuals with severe insulin deficiency
will have high glycaemic variability and high hypoglycaemia
risk whatever the underlying diabetes aetiology or classifica-
tion. Identifying individuals with apparent type 2 diabetes
who have developed severe insulin deficiency could assist
appropriate management, including consideration of the
intensive strategies to minimise hypoglycaemia traditionally
used in type 1 diabetes.
We therefore aimed to determine whether rCP
measurement can be used to assess risk of hypoglycaemia in
insulin-treated patients with a clinical diagnosis of type
2 diabetes.
Methods
We assessed whether severe insulin deficiency defined by a
low rCP is associated with high rates of hypoglycaemia and
glucose variability, as assessed by continuous glucose
monitoring (CGM), in patients with insulin-treated type 2
diabetes. We replicated our findings using questionnaire-
based assessment of hypoglycaemia in a large population
cohort of patients with insulin-treated type 2 diabetes and a
cohort with type 1 diabetes as a comparison group.
Ethics approval Ethics approvals were obtained from the
National Research Ethics Service (NRES) Committee South
West (UK).
CGM assessment of glucose variability
and hypoglycaemia in insulin-treated patients with type 2
diabetes with low or preserved endogenous insulin
secretion
ParticipantsWe recruited 17 insulin-treated individuals with
a clinical diagnosis of type 2 diabetes and severe insulin
deficiency and a control group of 17 matched individuals with
relatively preserved endogenous insulin secretion. All
participants were diagnosed aged 35 years or older, treated
without insulin for at least 2 years beyond diagnosis and had
an eGFR > 30 ml min−1 (1.73 m)−2. Participants were recruit-
ed based on known C-peptide result and clinical characteris-
tics in the Diabetes Alliance for Research in England (DARE)
study, http://www.diabetesgenes.org/content/diabetes-
alliance-research-england-dare-previously-known-exeter-
research-alliance-extra-stud, an unselected population-based
study of adults with diabetes in Devon (UK), recruited pre-
dominantly through primary care. The 17 participants with
severe insulin deficiency (rCP < 200 pmol/l) were individually
matched by sex and HbA1c (±10 mmol/l) with a control par-
ticipant who had preserved endogenous insulin secretion
(rCP > 600 pmol/l). C-peptide categories were chosen based
on previously reported thresholds for severe insulin
deficiency/high hypoglycaemia risk in type 1 diabetes
(< 200 pmol/l) and for type 2 diabetes/insulin requirement
(> 600 pmol/l) [6].
Baseline visit Participants attended non-fasting within 5 h of a
meal, without restriction on snacks or other intakes. Following
informed consent, baseline characteristics were recorded and
blood taken for repeat rCP, HbA1c and islet autoantibody
status (GAD/islet antigen 2 [IA2]). Clarke’s Hypoglycaemia
Questionnaire [17] was completed by all participants.
CGM At the baseline visit, participants commenced at least
three consecutive days’ CGM (iPro2 Professional; Medtronic,
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Watford, UK). For calibration purposes, participants were
asked to record four self-monitoring blood glucose tests daily
over the CGM period.
The following criteria were required for CGM data to be
included in analysis [18]: three or more self-monitoring of
blood glucose (SMBG) calibrations in 24 h; no missing data
points; correlation between SMBG and iPro2 readings > 0.77
in 24 h; mean difference between SMBG and iPro2 readings
for each 24 h (MAD%) < 28% and a minimum of 24 h data
meeting these criteria.
CGM analysis The mean glucose, SD of glucose
measurements, mean amplitude of glycaemic excursions
(MAGE) and low blood glucose index (LBGI) were analysed
for each individual using EasyGV online software [19], N.
Hill, University of Oxford, Oxford, UK; https://www.phc.ox.
ac.uk/research/technology-outputs/easygv.
An episode of hypoglycaemia was defined as ≥ 20 min at
or below the interstitial glucose level of 4, 3 or 2.2 mmol/l, and
only complete once readings had been above the threshold for
> 20 min [19]. Results were converted to rates of
hypoglycaemia and duration of hypoglycaemia per person
per week, and by day (08:00–00:00 hours) and night
(00:00–08:00 hours).
Laboratory analyses C-peptide was analysed using the
automated Roche diagnostics (Manheim, Germany) E170
immuno-analyser (limit of detection 3.3 pmol/l, inter- and
intra-assay coefficients of variation < 4.5% and < 3.3%,
respectively) in the Blood Sciences department, Royal
Devon and Exeter Hospital.
GAD65 and IA2 autoantibodies were assessed using the
RSR Elisa kits (Cardiff, UK) on a Dynex DS2 automated
Elisa System (Dynex Technologies, Worthing, UK). Cut-offs
used were based on the 97.5th centile for 1600 adults without
diabetes; the reference positive value was > 11 U/ml for
GAD65 and > 15 U/ml for IA2.
Statistical analysis Differences in continuous measures of
glucose variability and hypoglycaemia and baseline
characteristics between low- and high-C-peptide pairs were
assessed using paired t tests, as differences in paired data
approximated normal distribution. For comparing proportions,
χ2 tests were used.
To assess whether our findings were independent of insulin
regime, a potential source of confounding [20, 21],
we performed an additional unpaired sensitivity analysis
comparing measures of glucose variability and hypo-
glycaemia between C-peptide groups, with adjustment for
use of prandial or mixed insulin using ANCOVA and (for
rates) Poisson regression.
Assessment of the relationship between rCP
and self-reported hypoglycaemia in patients
with insulin-treated diabetes
ParticipantsFour hundred and sixty-five (256 type 2 diabetes,
209 type 1 diabetes, reported clinician diagnosis) insulin-
treated patients in the DARE study (see above), were
recruited by postal invitation (existing DARE cohort) or at
DARE recruitment visit, of whom 27 also participated in our
CGM cohort (above).
C-peptide assessment Non-fasting C-peptide was measured
at participants’ recruitment visit or, for participants previously
recruited to the DARE study, with prior written informed
consent, measured on residual plasma from routine non-
fasting clinical laboratory analysis.
Hypoglycaemia questionnaires Participants completed a
modified Clarke’s Hypoglycaemia Questionnaire [17, 22] by
post (existing DARE cohort) or at DARE recruitment visit.
Hypoglycaemia awareness was assessed by calculating the
Clarke score [17]: questions are each allocated a score of 0
(aware) or 1 (reduced awareness), and the score for the seven
questions added together. A score of 4 or more is classed as
‘reduced awareness’, as previously reported [17].
Clarke’s Hypoglycaemia question 5 (frequency of episodes
in the last month where blood glucose < 3.5 mmol/l, with
symptoms) and question 6 (episodes where blood glucose
< 3.5 mmol/l, without symptoms) categorise self-reported
frequency into groups. Thus, for analysis we assigned an
estimated frequency per answer for an approximation of
frequency in the last month: 1–3 episodes in the last month
became 2; one episode per week became 1 × 4 = 4; two or
three episodes per week became 2.5 × 4 = 10; four or five
episodes per week became 4.5 × 4 = 18 and almost daily was
estimated at 25 episodes per month.
Statistical analysis Rates of self-reported hypoglycaemia
were assumed to follow a Poisson distribution, so data are
presented as incidence rates and incidence rate ratios. We
compared rates of self-reported hypoglycaemia < 3.5 mmol/l
(Clarke questions 5 and 6, events per person per month) in
individuals with a clinical diagnosis of type 2 diabetes with
and without rCP < 200 pmol/l using the z test. CIs around rates
were calculated using the Poisson distribution. We compared
the proportion of participants reporting at least one episode of
hypoglycaemia in Clarke questions 3–6, and the proportion
with calculated reduced hypoglycaemia awareness (Clarke
score ≥ 4), using the χ2 test.
To assess whether differences between groups were due to
confounding by differences in clinical features associated with
hypoglycaemia and insulin type [21], we assessed the OR
(proportions, logistic regression) and rate ratio (questions 5
Diabetologia
and 6 rate, Poisson regression) for the above outcomes with
and without adjustment for age, sex, HbA1c and use of
prandial or mixed insulin (vs intermediate- or long-acting
insulin only). These covariates were associated with self-
reported hypoglycaemia rate in univariate analysis
(p < 0.002 for all).
We repeated this analysis in individuals with type 1 diabetes.
To ensure results did not reflect poor accuracy of reported
clinical diagnosis, we also repeated analysis in subgroups
defined by the following restrictive criteria for type 1 and 2
diabetes: (1) type 1 diabetes–clinician diagnosis of type 1
diabetes, diabetes onset before age 35 years and
insulin treatment within 6 months of diagnosis and (2) type
2 diabetes–clinician diagnosis of type 2 diabetes, diagnosis ≥
age 35 years and time to insulin ≥ 2 years.
Results
Assessment of glucose variability and hypoglycaemia
in insulin-treated patients with type 2 diabetes with low
or preserved endogenous insulin secretion
Participant characteristics and data quality Participant
characteristics are shown in Table 1. Mean CGM glucose
(10.2 vs 9.9 mmol/l, p = 0.5), HbA1c, age, duration of diabetes
and BMI were similar when comparing the low- and high-C-
peptide groups. However, participants with severe insulin
deficiency had progressed more rapidly to insulin treatment,
received higher insulin doses and were more likely to receive
basal bolus insulin therapy and have positive islet cell
autoantibodies.
The mean duration of CGM recording meeting inclusion
criteria for analysis was 4.1 (range 1–6.2) days; this was
similar between the two groups (4.3 [range 1–6.2] vs 3.9
[1.3–6] days in the low- vs high-C-peptide group,
respectively, p = 0.34).
SD of glucose readings on CGM was higher in the low-C-
peptide group Glucose variability was greater in the low-C-
peptide group: SD of glucose measurements 4.15 mmol/l
(95% CI 3.67, 4.64) vs 3.01 mmol/l (2.65, 3.38), p < 0.001.
MAGE did not differ between groups (7.05 mmol/l [5.9, 8.2]
vs 6.03 mmol/l [4.8, 7.3], p = 0.1).
Hypoglycaemia is markedly more frequent in individuals
with low C-peptide Of the 17 participants in the low-C-
peptide group, 16 (94%) experienced at least one episode of
hypoglycaemia on CGM (≥ 20 min, ≤ 4 mmol/l) compared
with 7/17 (41%) in the high-C-peptide group (p < 0.001)
(Fig. 1a).
The rate of hypoglycaemia (≥ 20min, ≤ 4mmol/l) on CGM
was higher in the low-C-peptide group than in the high-C-
peptide group (5.5 [95% CI 4.4, 6.7] vs 2.1 [1.4, 2.9] episodes
per person per week, p = 0.004) (Fig. 1b). The total duration of
hypoglycaemia was also higher in the low-C-peptide group
(mean 630 [95%CI 329, 931] vs 223 [14, 431] min per person
per week, p = 0.01) (Fig. 1c).
The frequency and total duration of episodes of more
significant hypoglycaemia (interstitial glucose ≤ 3 mmol/l)
were also higher in the low-C-peptide group (1.8 [95% CI
1.2, 2.6] vs 0.4 (0.1, 0.8) episodes per person per week,
p = 0.037; 199 (47, 352) vs 31 [0, 83] min per person per
week, p = 0.049) (Fig. 1b, c). All hypoglycaemia episodes
Table 1 Characteristics of the
CGM-assessed hypoglycaemia
cohort
Characteristic C-peptide
< 200 pmol/l
C-peptide
> 600 pmol/l
p value
No. of participants 17 17 –
C-peptide, pmol/l 38.9 (10.3, 67.4) 1238.3 (906.5, 1570.1) –
Mean glucose on CGM, mmol/l 10.2 (9.1, 11.3) 9.9 (8.6, 11.1) 0.50
HbA1c, mmol/mol 72.0 (65.5, 78.5) 72.2 (66.1, 78.3) 0.88
HbA1c, % 8.7 (8.1, 9.3) 8.7 (8.4, 9.3) 0.88
Male sex, n (%) 11 (65) 11 (65) –
Age, years 72.8 (68.4, 77.2) 71.8 (68.5, 75.1) 0.71
Diabetes duration, years 24.5 (19.0, 30.0) 19.8 (16.8, 22.9) 0.13
BMI, kg/m2 26.6 (24.8, 28.4) 27.9 (26.1, 29.8) 0.19
Time to insulin, months 62 (37, 87) 111 (76, 145) 0.03
Total dose of insulin in 24 h, U/kg 0.71 (0.61, 0.8) 0.52 (0.39, 0.64) 0.007
Use of prandial (basal bolus or mixed) insulin, % 100 59 0.003
Proportion with ≥ one islet autoantibody, % 59 (28, 100) 6 (2, 33) <0.001
Values reported are mean (95% CI) unless stated otherwise
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below 3 mmol/l in the high-C-peptide group occurred at night
(00:00–08:00 hours); in contrast 7/17 (41%) of participants
with low C-peptide experienced daytime hypoglycaemia
≤3 mmol/l, with a mean rate of 1.3 (0.8, 2.0) episodes per
person per week (p = 0.01). Rates of severe hypoglycaemia
≤ 2.2 mmol/l were low and did not significantly differ by C-
peptide status (0.5 [0.2, 1] vs 0.1 [0,0.4] episodes per person
per week, p = 0.26) (Fig. 1b). The LBGI was substantially
higher in those with low C-peptide (5.5 [3.8, 7.3] vs 1.9 [0.8,
3.0], p < 0.001).
Associations between C-peptide and hypoglycaemia were
independent of insulin regimen In unpaired sensitivity
analysis, the association between C-peptide group and both
glucose variability and hypoglycaemia was not substantially
altered by adjustment for insulin regimen (see electronic
supplementary material [ESM] Tables 1 and 2).
Replication using self-reported hypoglycaemia
in a population cohort
Participant characteristics Participant characteristics for the
hypoglycaemia questionnaire cohort are shown in Table 2
(type 2 diabetes) and ESM Table 3 (type 1 diabetes compari-
son cohort). Fourteen per cent of participants with a clinical
diagnosis of insul in- t reated type 2 diabetes had
rCP < 200 pmol/l. These participants had similar age, diabetes
duration and HbA1c to participants with retained C-peptide
but had lower BMI and time to insulin and greater use of
prandial insulin.
Low C-peptide is associated with higher rates of self-
reported hypoglycaemia in patients with insulin-treated
type 2 diabetes In participants with insulin-treated type 2
diabetes, self-reported hypoglycaemia was approximately
twice as common in those with rCP < 200 pmol/l compared
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Fig. 1 Hypoglycaemia measured by CGM in individuals with rCP < 200
pmol/l vs > 600 pmol/l. Light grey section of bars, glucose threshold ≤ 4
mmol/l; dark grey sections, ≤ 3 mmol/l; black sections, ≤ 2.2 mmol/l.
Error bars represent 95% CI. (a) Proportion of individuals with one or
more hypoglycaemia episodes. (b) Rate of hypoglycaemia (no. of epi-
sodes per person per week). (c) Hypoglycaemia duration (minutes per
person per week). **p≤0.01 and ***p<0.001 for rCP <200 pmol/l vs
>600 pmol/l
Table 2 Characteristics of the
questionnaire-assessed
hypoglycaemia cohort with
insulin-treated type 2 diabetes
Characteristics C-peptide
< 200 pmol/l
C-peptide
≥ 200 pmol/l
p value
No. (%) of participants 35 (14) 221 (86) –
HbA1c, mmol/mol 71.3 (66.0, 76.6) 66.9 (64.7, 69.1) 0.1
HbA1c, % 8.7 (8.2, 9.2) 8.3 (8.1, 8.5) 0.1
Male sex, % 60 (42, 76) 63 (56, 69) 0.7
Age, years 68.2 (64.4, 72.0) 66.0 (64.7, 73) 0.2
Duration of diabetes, years 16.2 (13.1, 19.5) 14.1 (13.1, 15.2) 0.2
BMI, kg/m2 28.2 (26.4, 30.0) 32.2 (31.5, 33.0) <0.001
Time to insulin, months 48.4 (28.4, 68.5) 84.1 (73.2, 95.0) 0.01
Insulin dose in 24 h, U/kg 0.73 (0.58, 0.87) 0.63 (0.56, 0.69) 0.3
Use of prandial (basal bolus or mixed) insulin, % 84 (64, 95) 44 (36, 51) <0.001
Values are reported as mean (95% CI) unless stated otherwise
Diabetologia
with those with rCP ≥ 200 pmol/l (Fig. 2). The mean (95%CI)
rate of occurrence of symptoms (Clarke question 5) in low- vs
high-C-peptide participants was 3.5 (2.9, 4.2) vs 1.8 (1.6, 2.0)
episodes per person per month (p < 0.001). The mean rate
without symptoms (Clarke question 6) was 1.4 (1.0,1.8) vs
0.69 (0.58, 0.81) episodes per person per month (p < 0.001)
in the low- vs high-C-peptide group. Severe hypoglycaemia
resulting in unconsciousness or seizures (Clarke question 4)
was more common in those with low C-peptide (OR 5.0 [95%
CI 2.0, 12.7]) but the frequency of episodes needing external
help (Clarke question 3) was not different (p = 0.5). ORs and
rate ratios for self-reported hypoglycaemia (Clarke questions
3–6), by C-peptide status, are given in ESM Table 4, without
and with adjustment for prandial insulin use, age, sex and
HbA1c. Results were not substantially altered by adjusting
for these covariates.
Questionnaire-defined hypoglycaemia unawareness
(Clarke score ≥ 4) occurred in 11.4% and 5.0% of those with
low and high C-peptide, respectively; the difference was
statistically significant only in adjusted analysis (unadjusted
p = 0.17, adjusted p = 0.005) (ESM Table 4).
The relationship between self-reported hypoglycaemia
and C-peptide is similar in type 1 and type 2 diabetes In
participants with type 1 diabetes, rCP < 200 pmol/l was also
associated with an approximate doubling of rate of self-
reported hypoglycaemia in the previous month with or
without symptoms: mean (95% CI) rate with symptoms
(Clarke question 5) (low vs high C-peptide) 6.3 (6.0, 6.7) vs
3.0 (2.4, 3.7) episodes per person per month (p < 0.001);
without symptoms (question 6) 1.7 (1.5, 1.9) vs 0.6 (0.36,
0.98) episodes per person per month (p < 0.001). The
difference in hypoglycaemia unawareness (Clarke score ≥ 4)
was not statistically different between C-peptide groups
(11.7% [95% CI 7.4, 17.4] and 3.3% [0, 17.2] for those with
C-peptide < 200 pmol/l and ≥ 200 pmol/l, respectively,
p = 0.2). Results were similar after adjustment for clinical
features and prandial insulin (ESM Table 4).
Thirteen per cent of patients with insulin-treated type 2
diabetes have severe insulin deficiency, even when defined
by more strict criteria When using strict criteria for type 2
diabetes (clinician diagnosis of type 2 diabetes, age at
diagnosis ≥ 35 years and insulin initiation ≥ 2 years from
diagnosis, n = 203), 13% (95% CI 8.5, 18) of individuals
meeting these criteria had C-peptide < 200 pmol/l. When
restricting analysis to this cohort, results were similar, with
higher rates of hypoglycaemia in those with low vs high C-
peptide (Clarke question 5, 3.0 vs 1.9 episodes per person per
month [p < 0.001]; Clarke question 6, 1.6 vs 0.5 episodes per
person per month [p < 0.001]). Results were similar for par-
ticipants meeting strict criteria for type 1 diabetes (n = 188), of
whom 12% had rCP ≥ 200 pmol/l (Clarke question 5, 6.1 vs
3.6 episodes per person per month [p < 0.001]; Clarke ques-
tion 6, 1.8 vs 0.7 episodes per person per month [p < 0.001]).
Hypoglycaemia rates in type 1 and type 2 diabetes with
low insulin secretion are broadly similar after accounting
for clinical features and insulin type In unadjusted analysis,
type 1 diabetes with C-peptide < 200 pmol/l was associated
with a 1.7 times higher rate of hypoglycaemia than the rate
reported by participants with type 2 diabetes and C-peptide
< 200 pmol/l: rate ratio for episodes of hypoglycaemia
< 3.5 mmol/l in the previous month in those with
rCP < 200 pmol/ l for type 1 vs type 2 diabetes
(Clarke questions 5 and 6 combined) was 1.66 (95% CI
1.39,1.97) (p < 0.001). However, after adjustment for prandial
insulin use, HbA1c, sex and age this difference was modest
and did not reach statistical significance (rate ratio 1.18 [0.96,
1.45], p = 0.12).
Discussion
Our results demonstrate that patients with insulin-treated type
2 diabetes but low C-peptide levels have markedly increased
incidence of hypoglycaemia in comparison to those with
retained C-peptide, whether measured by CGM or self-
reported. On CGM, glycaemic variability (when defined by
SD, the most robust measure [19, 23–25]), frequency and
duration of hypoglycaemia were markedly increased in those
with severe insulin deficiency. More significant daytime
hypoglycaemia (< 3 mmol/l, [26]) was entirely confined to
these participants. These differences occurred despite similar
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Fig. 2 Frequency of self-reported hypoglycaemia (< 3.5 mmol/l) by C-
peptide status in patients with insulin-treated type 2 diabetes (n=256).
Light grey bars, rCP < 200 pmol/l; dark grey bars, rCP ≥ 200 pmol/l.
Rates of aware and unaware episodes derived from Clarke questions 5
and 6, respectively. Error bars represent 95% CI. ***p<0.001 for rCP <
200 pmol/l vs ≥ 200 pmol/l
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glycaemic control in those with and without preserved
endogenous insulin secretion. Severe insulin deficiency was
not uncommon in participants with insulin-treated type 2
diabetes in our cohort, occurring in 13% of participants even
when strict clinical criteria for classification were applied.
While many of these participants may have diabetes of
autoimmune aetiology, this was not clinically recognised or
apparent, with low-C-peptide participants having late-onset
diabetes, raised BMI and time from diagnosis to insulin
treatment of several years.
Comparison with other studies
Our findings of a strong association between C-peptide and
hypoglycaemia are consistent with previous findings in type 1
diabetes using self-reported hypoglycaemia [1, 3, 9, 10, 19]
and CGM studies in type 1 diabetes demonstrating higher SD
or CV (SD/glucose), defined glucose variability and
hypoglycaemia in individuals with lower C-peptide, including
after islet transplant [27–29]. In these studies, C-peptide was
measured using a mixed meal tolerance test, which is not
suitable for routine use in clinical practice. One study
examined the correlation between fasting C-peptide and
glucose variability (CGM SD) and found inverse associations
in both type 1 diabetes and insulin-treated type 2 diabetes,
although hypoglycaemia was not examined [30].
The relationship between C-peptide levels and frequency
of hypoglycaemia in those with a clinical diagnosis of type 2
diabetes is less widely recognised. The frequency of
hypoglycaemia in type 2 diabetes is known to be associated
with diabetes duration [31], and is markedly higher in
individuals treated with insulin for a long period than in those
in the initial stages of treatment [32]. It has also recently been
shown that individuals with type 2 diabetes who were unable
to achieve the ACCORD study’s treatment target of
HbA1c < 6.0% (42 mmol/mol) due to severe hypoglycaemia
had lower C-peptide, with an OR of 23 for low C-peptide
(baseline fasting C-peptide < 0.15 nmol/l) [33].
While the potential utility of rCP as a biomarker for
hypoglycaemia in individuals with diabetes has not been
previously examined, previous research has shown that this
test is highly correlated with mixed-meal-test-measured C-
peptide [11] and has similar or superior utility to glucagon-
stimulated C-peptide assessment for differentiating between
type 1 and type 2 diabetes [34].
Strengths and limitations
This is to our knowledge the first study to examine the
relationship between C-peptide and CGM-assessed hypo-
glycaemia in type 2 diabetes and the first to assess the
potential utility of rCP for stratification of hypoglycaemia risk.
This is an inexpensive test that can be measured at the point of
clinical contact and could therefore easily be incorporated into
clinical practice. Our additional study in a larger cohort using
self-reported hypoglycaemia as an outcome strengthens our
findings. We have assessed an older adult population in our
study, an age group wherein hypoglycaemia is often not
recognised, and consequences are more severe [35] and where
risk biomarker-based stratification would therefore be
particularly helpful.
Aweakness of our study is that C-peptide assessment in our
replication study was in the most part performed on routine
non-fasting plasma–EDTA samples received by our
laboratory, therefore did not assess concurrent glucose or
timing of samples in relation to meals. We have previously
shown concurrent hypoglycaemia may result in reduced rCP
levels and recommended that when assessing rCP, concurrent
hypoglycaemia is excluded and a sample taken 1–5 h post
meal [11]. An additional weakness is that we cannot fully
account for potential confounders which may alter the
relationship between C-peptide and hypoglycaemia. In our
CGM study, although most clinical characteristics were very
similar between groups, prandial insulin use was more
common in those with low C-peptide. This may reflect a
causal association (those with low C-peptide and high glucose
variability are likely to need prandial insulin for glycaemic
control), although insulin regimen may directly influence
hypoglycaemia [20, 21]. Importantly, adjusting for insulin
regime in our analysis did not alter our findings. In our
questionnaire study, rates of self-reported hypoglycaemia
were likely to be very dependent on rates of self-monitoring
of blood glucose levels, which was not assessed.
Clinical implications
Our results suggest that an rCP sample can identify patients
with insulin-treated type 2 diabetes who have a markedly
increased risk of hypoglycaemia. These patients could not be
identified by their clinical characteristics and only 59% would
be identified by islet autoantibody testing, supporting the
potential utility of rCP testing, which is practical, stable and
inexpensive and therefore ideal for clinical use.
Identifying patients with insulin-treated type 2 diabetes at
high risk of hypoglycaemia would be clinically helpful in
guiding management (e.g. in setting appropriate glycaemic
targets and levels of glucose monitoring) and would
potentially allow consideration of treatment strategies for high
glucose variability traditionally used in type 1 diabetes, such
as carbohydrate counting and use of subcutaneous insulin
pumps. An additional area where a robust, easily measurable
biomarker for hypoglycaemia risk would be useful is in
stratification of hypoglycaemia risk in relation to driving.
Our CGM data showing no daytime episodes ≤ 3 mmol/mol
in those with high rCP and an OR of 9.5 for self-reported
severe hypoglycaemia (unconscious or fit, adjusted analysis)
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in the last year in those with low rCP are of interest in this
regard and warrant further investigation.
Unanswered questions and future research
In this study, we used a previously defined threshold for
hypoglycaemia risk based on previous studies in type 1
diabetes, and in our CGM cohort we excluded participants
with C-peptide between 200 and 600 pmol/l (23% and 7%
of participants in our type 2 diabetes and type 1 diabetes
questionnaire cohorts, respectively). The relationship between
C-peptide and glucose variability in previous literature is
continuous but non-linear, with a very strong association at
low but not high C-peptide levels [28, 29, 36]. This is similar
to the relationship observed with self-reported hypoglycaemia
in our cohort (ESM Fig. 1). Further studies are needed to
define optimal clinical cut-offs in obese populations with type
2 diabetes or alternatively to examine more complex
approaches to risk prediction which might account for C-
peptide as a continuous variable alongside other predictive
features. Larger studies are needed to assess rCP against
robust clinically important hypoglycaemia outcomes such as
severe hypoglycaemia and to formally assess effectiveness
and cost effectiveness of biomarker-based stratification of
management. While it is likely that our results will be equally
applicable to individuals diagnosed with type 1 diabetes, we
did not directly assess this in our CGM study, which is thus an
area of future work.
Conclusions
Low rCP is associated with increased glucose variability and
hypoglycaemia in patients with insulin-treated type 2 diabetes
and represents a practical, stable and inexpensive biomarker
for assessment of hypoglycaemia risk.
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